Feb 18, 2026Rapamycin in Older Adults: PEARL Trial Findings on Dose, Sex Differences, and Body CompositionThe PEARL trial tested low-dose weekly rapamycin in healthy older adults. The primary endpoint — visceral fat reduction — was not met. Secondary analyses suggested lean tissue effects at higher doses in women, but these require confirmation in adequately powered trials.
Feb 17, 2026Caloric Restriction Mimetics in 2025: Multi-Pathway Geroprotectors Under Clinical EvaluationA 2025 Biogerontology review maps geroprotective compounds targeting AMPK, mTOR, and autophagy pathways. Most remain at biomarker endpoints; hard longevity data in humans is largely absent.
Feb 14, 2026Supplement Cycling Protocols: Rapamycin, Senolytics, and Adaptogens — Evidence for Intermittent UseNot all supplements should be taken daily. Rapamycin is typically dosed weekly to preserve mTOR signaling windows. Senolytics (dasatinib + quercetin, fisetin) are used in short intermittent bursts. Even some adaptogens are cycled to prevent tolerance. This article maps the rationale and evidence for each.
Feb 1, 2026Rapamycin and mTOR: Longevity Mechanism, PEARL Trial, and Low-Dose Protocol RisksRapamycin extends lifespan in every organism tested and the PEARL trial is the first human RCT for longevity use. mTOR inhibition reduces cellular senescence and improves immune function. Off-label use carries real risks that must be understood before consideration.